Longchai Jiangxue Formula for Myeloproliferative Neoplasms:A Multicenter Randomized Controlled Trial
Objective To evaluate the efficacy and safety of Longchai Jiangxue Formula(LCJX)in the treatment of myeloproliferative neoplasm(MPN).Methods A multicenter double-blinded randomized controlled trial was conducted.One hundred patients with MPN were randomly assigned to the experimental group and control group,with 50 patients in each group.Both groups received conventional treatment and Yigong Formula.The experimental group received LCJX additionally.The treatment lasted for 4 months.The effective rate,blood cell counts,MPN-10 scores,disease progression,and thrombotic or bleeding events were observed.The adverse events were recorded during the treatment.Results A total of 40 cases in the experimental group and 41 cases in the control group completed the trial and were included for statistical analysis.Compared with the control group,the effective rate increased in the experimental group(86.5%vs.56.1%,P<0.05),the platelet count and hematocrits were decreased in the experimental group(P<0.05),the total MPN-10 scores,the symptom score of early satiety,and the symptom score of night sweats were all declined in the experimental group(P<0.05).No disease progression,thrombotic or bleeding events occurred during the treatment.Compared with the control group,the rate of hepatic dysfunction was decreased in the experimental group(5.0%vs.9.7%,P<0.05),and no adverse events except for mild hepatic dysfunction were observed in both groups during the treatment.Conclusions LCJX can increase the effective rate,decrease blood counts,and improve symptoms in the treatment of MPN,with no more adverse events.LCJX is proven to be effective and safe in the treatment of MPN.
myeloproliferative neoplasmsessential thrombocythemiapolycythemia veraChinese medicineLongchai Jiangxue Formulaintegrative medicine